X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs SUN PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE SUN PHARMA CADILA HEALTHCARE/
SUN PHARMA
 
P/E (TTM) x 35.2 15.3 229.5% View Chart
P/BV x 9.1 3.6 251.5% View Chart
Dividend Yield % 0.7 0.2 317.6%  

Financials

 CADILA HEALTHCARE   SUN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-16
SUN PHARMA
Mar-16
CADILA HEALTHCARE/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs4541,201 37.8%   
Low Rs305706 43.1%   
Sales per share (Unadj.) Rs96.1117.5 81.8%  
Earnings per share (Unadj.) Rs14.919.6 75.9%  
Cash flow per share (Unadj.) Rs17.823.8 74.9%  
Dividends per share (Unadj.) Rs3.201.00 320.0%  
Dividend yield (eoy) %0.80.1 804.2%  
Book value per share (Unadj.) Rs52.3130.5 40.1%  
Shares outstanding (eoy) m1,023.742,406.60 42.5%   
Bonus/Rights/Conversions FV5:1--  
Price / Sales ratio x3.98.1 48.6%   
Avg P/E ratio x25.548.7 52.4%  
P/CF ratio (eoy) x21.340.1 53.1%  
Price / Book Value ratio x7.37.3 99.3%  
Dividend payout %21.55.1 421.6%   
Avg Mkt Cap Rs m388,4582,294,813 16.9%   
No. of employees `00015.414.7 104.7%   
Total wages/salary Rs m13,31747,971 27.8%   
Avg. sales/employee Rs Th6,371.119,169.8 33.2%   
Avg. wages/employee Rs Th862.43,253.0 26.5%   
Avg. net profit/employee Rs Th986.13,197.9 30.8%   
INCOME DATA
Net Sales Rs m98,376282,697 34.8%  
Other income Rs m9416,170 15.3%   
Total revenues Rs m99,317288,867 34.4%   
Gross profit Rs m23,82983,239 28.6%  
Depreciation Rs m3,02210,135 29.8%   
Interest Rs m4864,769 10.2%   
Profit before tax Rs m21,26274,505 28.5%   
Minority Interest Rs m-300-11,126 2.7%   
Prior Period Items Rs m5-19 -26.7%   
Extraordinary Inc (Exp) Rs m-25-6,852 0.4%   
Tax Rs m5,7169,349 61.1%   
Profit after tax Rs m15,22647,159 32.3%  
Gross profit margin %24.229.4 82.3%  
Effective tax rate %26.912.5 214.2%   
Net profit margin %15.516.7 92.8%  
BALANCE SHEET DATA
Current assets Rs m44,376308,646 14.4%   
Current liabilities Rs m34,071132,477 25.7%   
Net working cap to sales %10.562.3 16.8%  
Current ratio x1.32.3 55.9%  
Inventory Days Days5483 64.9%  
Debtors Days Days6288 71.1%  
Net fixed assets Rs m47,896133,606 35.8%   
Share capital Rs m1,0242,407 42.5%   
"Free" reserves Rs m48,746266,909 18.3%   
Net worth Rs m53,519314,042 17.0%   
Long term debt Rs m8,96431,167 28.8%   
Total assets Rs m100,163542,196 18.5%  
Interest coverage x44.716.6 269.2%   
Debt to equity ratio x0.20.1 168.8%  
Sales to assets ratio x1.00.5 188.4%   
Return on assets %15.79.6 163.8%  
Return on equity %28.415.0 189.5%  
Return on capital %34.317.8 193.2%  
Exports to sales %45.314.0 323.4%   
Imports to sales %5.93.1 188.9%   
Exports (fob) Rs m44,53739,572 112.5%   
Imports (cif) Rs m5,8388,882 65.7%   
Fx inflow Rs m44,88142,171 106.4%   
Fx outflow Rs m9,06921,583 42.0%   
Net fx Rs m35,81220,588 173.9%   
CASH FLOW
From Operations Rs m19,93867,694 29.5%  
From Investments Rs m-9,039-44,549 20.3%  
From Financial Activity Rs m-9,527-19,243 49.5%  
Net Cashflow Rs m1,3723,902 35.2%  

Share Holding

Indian Promoters % 74.8 63.7 117.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 5.1 161.8%  
FIIs % 5.9 23.0 25.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 8.3 132.5%  
Shareholders   44,069 133,026 33.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  NOVARTIS  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 18, 2017 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS